Clinical pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its metabolites

Clinical Pharmacokinetics

Volumn 42, Issue 3, 2003, Pages 205-221

  Hashimoto, Satoru ^a   Kobayashi, Atsuko ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLYCEROL 1 NITRATE; GLYCEROL 1,2 DINITRATE; GLYCEROL 1,3 DINITRATE; GLYCEROL 2 NITRATE; GLYCERYL TRINITRATE;

BIOTRANSFORMATION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; CLINICAL PRACTICE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DETOXIFICATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERANCE; DRUG USE; ENZYME METABOLISM; FUTUROLOGY; GENETIC VARIABILITY; HEMOCONCENTRATION; HEMODYNAMIC MONITORING; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; METABOLITE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RELIABILITY; REVIEW; STEADY STATE;

ADMINISTRATION, TOPICAL; AGING; BIOTRANSFORMATION; EXERCISE; HUMANS; MODELS, BIOLOGICAL; NITROGLYCERIN; POSTURE; TEMPERATURE; VASODILATOR AGENTS;

EID: 0037228274     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342030-00001     Document Type: Review

References (119)

1. Curry SH, Aburawi SM. Analysis, disposition and pharmacokinetics of nitroglycerin. Biopharm Drug Dispos 1985; 6 (3): 235-80
2. Bogaert MG. Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations. Clin Pharmacokinet 1987; 12 (1): 1-11
3. Taylor T, Taylor IW, Chasseaud LF, et al. Pharmacokinetics and metabolism of organic nitrate vasodilators. In: Bridges JW, Chasseaud LF, Gibson GG, et al., editors. Progress in drug metabolism. London: Taylor & Francis Ltd, 1987: 207-336
4. Bogaert MG. Clinical pharmacokinetics of nitrates. Cardiovasc Drugs Ther 1994: 8 (5): 693-9
5. Rosseel MT, Bogaert MG. GLC determination of nitroglycerin and isosorbide dinitrate in human plasma. J Pharm Sci 1973; 62 (5): 754-8
6. Bogaert MG, Rosseel MT. Plasma levels in man of nitroglycerin after buccal administration. J Pharm Pharmacol 1972; 24 (9): 737-8
7. Yap PS, Fung HL. Pharmacokinetics of nitroglycerin in rats. J Pharm Sci 1978; 67 (4): 584-6
8. Armstrong PW, Armstrong JA, Marks GS. Blood levels after sublingual nitroglycerin. Circulation 1979; 59 (3): 585-8
9. Wei JY, Reid PR. Quantitative determination of trinitroglycerin in human plasma. Circulation 1979; 59 (3): 588-92
10. Noonan PK, Williams RL, Benet LZ. Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. J Pharmacokinet Biopharm 1985; 13 (2): 143-57
11. Han C, Gumbleton M, Lau DT, et al. Improved gas chromatographic assay for the simultaneous determination of nitroglycerin and its mono- and dinitrate metabolites. J Chromatogr 1992; 579 (2): 237-45
12. Booth BP, Bennett BM, Brien JF, et al. Assay of glyceryl trinitrate, isosorbide dinitrate, and their metabolites in plasma by large-bore capillary column gas-liquid chromatography. Biopharm Drug Dispos 1990; 11 (8): 663-77
13. Santoro A, Rovati LC, Setnikar I, et al. Bioavailability and pharmacokinetic profile of glyceryl trinitrate and of glyceryl dinitrates during application of a new glyceryl trinitrate transdermal patch. Arzneimittel Forschung 2000; 50 (9): 779-85
14. Vaksmann G, Pariente-Khayat A, Godart F, et al. Effects of transdermal nitroglycerin in children with congestive heart failure: a doppler echocardiographic study. Pediatr Cardiol 2001; 22 (1): 11-3
15. Baba S, Shinohara Y, Sano H, et al. Application of high-performance liquid chromatography with synchronized accumulating radioisotope detector to analysis of glyceryl trinitrate and its metabolites in rat plasma. J Chromatogr 1984; 305 (1): 119-26
16. Armstrong JA, Slaughter SE, Marks GS, et al. Rapid disappearance of nitroglycerin following incubation with human blood. Can J Physiol Pharmacol 1980; 58 (5): 459-62
17. Akiyama K, Hirota J, Takiguchi M, et al. The release of nitroglycerin absorbed into the central venous catheter. Surg Today 1997; 27 (10): 936-40
18. Altavela JL, Haas CE, Nowak DR, et al. Clinical response to intravenous nitroglycerin infused through polyethylene or polyvinyl chloride tubing. Am J Hosp Pharm 1994; 51 (4): 490-4
19. Klemsdal TO, Mundal HH, Bredesen JE, et al. Transdermal nitroglycerin: clinical and pharmacokinetic consequences of renewing the patch and the application site. Eur J Clin Pharmacol 1997; 52 (5): 379-81
20. Han C, Jung P, Sanders SW, et al. Pharmacokinetics of nitroglycerin and its four metabolites during nitroglycerin transdermal administration. Biopharm Drug Dispos 1994; 15 (2): 179-83
21. Hashimoto S, Yamauchi E, Kobayashi A, et al. The pharmacokinetics of trinitroglycerin and its metabolites in patients with chronic stable angina. Br J Clin Pharmacol 2000; 50 (4): 373-6
22. Bauer JA, Fung HL. Arterial versus venous metabolism of nitroglycerin to nitric oxide: a possible explanation of organic nitrate venoselectivity. J Cardiovase Pharmacol 1996; 28 (3): 371-4
23. Hodgson JR, Lee CC. Trinitroglycerol metabolism: denitration and glucuronide formation in the rat. Toxicol Appl Pharmacol 1975; 34 (3): 449-55
24. Bauer JA, Fung HL. Specific binding of nitroglycerin to coronary artery microsomes: evidence of a vascular nitrate binding site. Biochem Pharmacol 1996; 52 (4): 619-25
25. Ignarro LJ, Lippton H, Edwards JC. et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981; 218 (3): 739-49
26. Chung SJ, Fung HL. Relationship between nitroglycerin-induced vascular relaxation and nitric oxide production: probes with inhibitors and tolerance development. Biochem Pharmacol 1993; 45 (1): 157-63
27. Feelisch M, Kelm M. Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells. Biochem Biophys Res Commun 1991; 180 (1): 286-93
28. Feelisch M, Brands F, Kelm M. Human endothelial cells bioactivate organic nitrates to nitric oxide: implications for the reinforcement of endothelial defence mechanisms. Eur J Clin Invest 1995; 25 (10): 737-45
29. Bennett BM, McDonald BJ, Nigam R, et al. Biotransformation of organic nitrates and vascular smooth muscle cell function. Trends Pharmacol Sci 1994; 15 (7): 245-9
30. Kurz MA, Boyer TD, Whalen R, et al. Nitroglycerin metabolism in vascular tissue: role of glutathione S-transferases and relationship between NO• and NO2-formafon. Biochem J 1993; 292 (2): 545-50
31. Haefeli WE, Gumbleton M, Benet LZ, et al. Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins. Clin Pharmacol Ther 1992; 52 (6): 590-6
32. Kwon HR, Green P, Curry SH. Pharmacokinetics of nitroglycerin and its metabolites after administration of sustained-release tablets. Biopharm Drug Dispos 1992; 13 (2): 141-52
33. Jensen KM, Dahl JB. Plasma concentrations of glyceryl trinitrate and its dinitrate metabolites after sublingual administration to volunteers: simultaneous determination of glyceryl trinitrate and its dinitrate metabolites. Arzneimittel Forschung 1994; 44 (8): 951-3
34. Auclair B, Sirois G, Ngoc AH, et al. Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system. Ther Drug Monil 1998; 20 (6): 607-11
35. Auclair B, Sirois G, Ngoc AH, et al. Novel pharmacokinetic modelling of transdermal nitroglycerin. Pharm Res 1998; 15 (4): 614-9
36. Marks GS, McLaughlin BE, MacMillan HF, et al. Differential biotransformation of glyceryl triditrate by red blood cell-supernatant fraction and pulmonary vein homogenate. Can J Physiol Pharmacol 1989; 67 (5): 417-22
37. Short RD, Dacre JC, Lee CC. A species and developmental comparison of trinitroglycerin metabolism in vitro. Biochem Pharmacol 1977; 26 (2): 162-3
38. Cossum PA, Roberts MS. Nitroglycerin disposition in human blood. Eur J Clin Pharmacol 1985; 29 (2): 169-75
39. Blei AT, Gottstein J, Fung HL. Role of the liver in the disposition of intravenous nitroglycerin in the rat. Biochem Pharmacol 1984; 33 (16): 2681-6
40. Bauer JA, Booth BP, Fung HL. Nitric oxide donors: biochemical pharmacology and therapeutics. Adv Pharmacol 1995; 34: 361-81
41. Needleman P, Jakschik B, Johnson EM Jr. Sullhydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther 1973; 187 (2): 324-31
42. Ignarro LJ, Gruetter CA. Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite: possible involvement of S-nitrosothiols. Biochim Biophys Acta 1980; 631 (2): 221-31
43. Feelisch M, Noack EA. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987; 139 (1): 19-30
44. Bennett BM, Kobus SM, Brien JF, et al. Requirement for reduced, unliganded hemoprotein for the hemoglobin- and myoglobin-mediated biotransformation of glyceryl trinitrate. J Pharmacol Exp Ther 1986; 237 (2): 629-35
45. Kohno M, Masumizu T, Mori A. ESR demonstration of nitric oxide production from nitroglycerin and sodium nitrite in the blood of rats. Free Radic Biol Med 1995; 18 (3): 451-7
46. Needleman P, Hunter FE. The transformation of glyceryl trinitrate and other nitrates by glutathione-organic nitrate reductase. Mol Pharmacol 1965: 1 (1): 77-86
47. Tsuchida S, Maki T, Salo K. Purification and characterization of glutathione transferases with an activity toward nitroglycerin from human aorta and heart: multiplicity of the human class Mu forms. J Biol Chem 1990; 265 (13): 7150-7
48. Servent D, Delaforge M, Ducrocq C, et al. Nitric oxide formation during microsomal hepatic denitration of glyceryl trinitrate: involvement of cytochrome P-450. Biochem Biophys Res Commun 1989; 163 (3): 1210-6
49. McDonald BJ, Bennett BM. Cylochrome P-450-medialed biotransformation of organic nitrates. Can J Physiol Pharmacol 1990; 68 (12): 1552-7
50. McDonald BJ, Bennett BM. Biotransformation of glyceryl trinitrate by rat aortic cytochrome P450. Biochem Pharmacol 1993; 45 (1): 268-70
51. Chung SJ, Fung HL. Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. J Pharmacol Exp Ther 1990; 253 (2): 614-9
52. Chung SJ, Fung HL. A common enzyme may be responsible for the conversion of organic nitrates to nitric oxide in vascular microsomes. Biochem Biophys Res Commun 1992; 185 (3): 932-7
53. Seth P, Fung HL. Biochemical characterization of a membrane-bound enzyme responsible for generating nitric oxide from nitroglycerin in vascular smooth muscle cells. Biochem Pharmacol 1993; 46 (8): 1481-6
54. Fung HL, Chong S, Kowaluk E, et al. Mechanisms for the pharmacologic interaction of organic nitrates with thiols: existence of an extracellular pathway for the reversal of nitrate vascular tolerance by N-acetylcysteine. J Pharmacol Exp Ther 1988; 245 (2): 524-30
55. Boesgaard S, Aldershvile J, Poulsen HE, et al. Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ Res 1994; 74 (1): 115-20
56. Sakanashi M, Matsuzaki T, Aniya Y. Nitroglycerin relaxes coronary artery of the pig with no change in glutathione content or glutathione S-transferase activity. Br J Pharmacol 1991; 103 (4): 1905-8
57. Aniya Y, Uehara N, Ishii C, et al. Evaluation of nitric oxide formation from nitrates in pig coronary arteries. Jpn J Pharmacol 1996; 71 (2): 101-7
58. Simon WC, Anderson DJ, Bennett BM. Inhibition of the pharmacological actions of glyceryl trinitrate after the electroporetic delivery of a glutathione S-transferase inhibitor. J Pharmacol Exp Ther 1996; 279 (3): 1535-40
59. Watkins PB. Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 1990; 10 (4): 235-50
60. McGuire JJ, Anderson DJ, McDonald BJ, et al. Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfate. Biochem Pharmacol 1998; 56 (7): 881-93
61. Bennett BM, McDonald BJ, Nigam R, et al. Inhibition of nitrovasodilator- and acetylcholine-induced relaxation and cyclic GMP accumulation by the cytochrome P-450 substrate, 7-ethoxyresorufin. Can J Physiol Pharmacol 1992; 70 (9): 1297-303
62. Bornfeldt KE, Axelsson KL. Studies on the effect of different inhibitors of arachidonic acid metabolism on glyceryltrinitrate-induced relaxation and cGMP elevation in bovine vascular tissue. Pharmacol Toxicol 1987; 60 (2): 110-6
63. Liu Z, Brien JF, Marks GS, et al. Lack of evidence for the involvement of cytochrome P-450 or other hemoproteins in metabolic activation of glyceryl trinitrate in rabbit aorta. J Pharmacol Exp Ther 1993; 264 (3): 1432-9
64. Yuan R, Sumi M, Benet LZ. Investigation of aortic CYP3A bioactivation of nitroglycerin in vivo. J Pharmacol Exp Ther 1997; 281 (3): 1499-505
65. Mayer B, Heinzel B, Klatt P, et al. Nitric oxide synthase-catalyzed activation of oxygen and reduction of cytochromes: reaction mechanisms and possible physiological implications. J Cardiovasc Pharmacol 1992; 20 Suppl. 12: S54-6
66. Bredt DS, Hwang PM, Glatt CE, et al. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991; 351 (6329): 714-8
67. Torfgård KE, Ahlner J. Mechanisms of action of nitrates. Cardiovasc Drugs Ther 1994; 8 (5): 701-17
68. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 1992; 99 (12): 8306-11
69. Curry SH, Lopez LM, Lambert CR, et al. Plasma concentrations and hemodynamic effects of intravenous, sublingual, and aerosolized nitroglycerin in patients undergoing cardiac catheterization. Biopharm Drug Dispos 1993; 14 (2): 107-18
70. Jensen KM, Mikkelsen S. Studies on the bioavailability of glyceryl trinitrate after sublingual administration of spray and tablet. Arzneimittel Forschung 1997; 47 (6): 716-8
71. Huber T, Merz PG, Harder S, et al. Bioequivalence of sublingual glycerol trinitrate: bioavailability and haemodynamic effects after application of a fluorochlorohydrocarbons-dependent spray and a new pumping system. Arzneimittel Forschung 1990; 40(12): 1319-22
72. de Mey C, Erb K, Zimmermann T, et al. Clinical pharmacological equivalence of a novel FCH-free GTN spray with low ethanol content vs a FCH-containing GTN spray. Eur J Clin Pharmacol 1995; 47 (5): 437-43
73. Landau AJ, Eberhardt RT, Frishman WH. Intranasal delivery of cardiovascular agents: an innovative approach to cardiovascular pharmacotherapy. Am Heart J 1994; 127 (6): 1594-9
74. Marchionni N, Ferrucci L, Fumagaili S, et al. Age-related changes in the pharmacodynamics of intravenous glyceryl trinitrate. Aging (Milano) 1990; 2 (1): 59-64
75. Booth BP, Brien JF, Marks GS, et al. The effects of hypothermic and normothermic cardiopulmonary bypass on glyceryl trinitrate activity. Anesth Analg 1994; 78 (5): 848-56
76. Sun JX, Piraino AJ, Morgan JM, et al. Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. J Clin Pharmacol 1995; 35 (4): 390-7
77. Torfgård K, Svedjeholm R, Hakansson E, et al. Tolerance development and arterial and venous tissue-/plasma levels of glyceryl trinitrate and glyceryl dinitrate in patients treated with nitroglycerin infusion. Arzneimittel Forschung 1995; 45 (9): 963-6
78. Harrison LI, Riedel DJ. Transdermal nitroglycerin systems: methods for comparison. Clin Ther 1991; 13 (3): 361-7
79. Williams RL, Thakker KM, John V, et al. Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations. Pharm Res 1991; 8 (6): 744-9
80. Wiegand A, Bauer KH, Bonn R, et al. Pharmacodynamic and pharmacokinetic evaluation of a new transdermal delivery system with a time-dependent release of glyceryl trinitrate. J Clin Pharmacol 1992; 32 (1): 77-84
81. Jewell RC, Banfield CR, Ruggirello DA, et al. Dose proportionality of transdermal nitroglycerin. Pharm Res 1992; 9 (10): 1284-9
82. Hutt V, Sauter K, Pabst G, et al. Bioequivalence evaluation of the metabolites 1,2- and 1,3-glyceryl dinitrate of two different glyceryl trinitrate patches after 12-h usage in healthy volunteers. Arzneimittel Forschung 1994; 44 (12): 1317-21
83. Santoro A, Rovati LC, Follet M, et al. Plasma levels of glyceryl trinitrate and dinitrates during application of three strengths of a new glyceryl trinitrate transdermal patch. Arzneimittel Forschung 2000; 50 (9): 786-94
84. Yu DK, Williams RL, Benet LZ, et al. Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing. Biopharm Drug Dispos 1988; 9 (6): 557-65
85. Laufen H, Leitold M. The pattern of glyceryl nitrates after oral administration of glyceryl trinitrate. Arzneimittel Forschung 1988; 38 (1): 103-5
86. Nakashima E, Rigod JF, Lin ET, et al. Pharmacokinetics of nitroglycerin and its dinitrate metabolites over a thirtyfold range of oral doses. Clin Pharmacol Ther 1990; 47 (5): 592-8
87. Armstrong PW, Moffat JA, Marks GS. Arterial-venous nitroglycerin gradient during intravenous infusion in man. Circulation 1982; 66 (6): 1273-6
88. Gumbleton M, Benet LZ. Pharmacological activity of the dinitrate metabolites of nitroglycerin following their oral administration to healthy volunteers. Br J Clin Pharmacol 1991; 31 (2): 211-3
89. Ogiso T, Iwaki M, Kanokogi A, et al. Percutaneous absorption of 1,3-dinitroglycerin and a trial of pharmacokinetic analysis. Chem Pharm Bull (Tokyo) 1990; 38 (10): 2829-33
90. Gumbleton M, Benet LZ. Simultaneous pharmacodynamic modeling of the non-steady-state effects of three oral doses of 1,3-glyceryl dinitrate upon blood pressure in healthy volunteers. J Pharmacokinet Biopharm 1993; 21 (5): 515-32
91. Salvemini D, Pistelli A, Anggard E. Vascular and anti-platelet actions of 1,2- and 1,3-glyceryl dinitrate. Br J Pharmacol 1993; 110 (3): 937-42
92. Müller P, Imhof PR, Burkart F, et al. Human pharmacological studies of a new transdermal system containing nitroglycerin. Eur J Clin Pharmacol 1982; 22 (6): 473-80
93. Riedel DJ, Wick KA, Hawkinson RW, et al. Drug release rates from four sizes of a new transdermal nitroglycerin adhesive patch. Clin Ther 1989; 11 (3): 409-16
94. Chong S, Fung HL. Kinetic mechanisms for the concentration dependency of in vitro degradation of nitroglycerin and glyceryl dinitrates in human blood: metabolite inhibition or cosubstrate depletion? J Pharm Sci 1989; 78 (4): 295-302
95. Gjesdal K, Klemsdal TO, Rykke EO, et al. Transdermal nitrate therapy: bioavailability during exercise increases transiently after the daily change of patch. Br J Clin Pharmacol 1991; 31 (5): 560-2
96. Weber S, de Lauture D, Rey E, et al. The effects of moderate sustained exercise on the pharmacokinetics of nitroglycerine. Br J Clin Pharmacol 1987: 23 (1): 103-5
97. Barkve TF, Langseth-Manrique K, Bredesen JE, et al. Increased uptake of transdermal glyceryl trinitrate during physical exercise and during high ambient temperature. Am Heart J 1986; 112 (3): 537-41
98. Lefebvre RA, Bogaert MG, Teirlynck O, et al. Influence of exercise on nitroglycerin plasma concentrations after transdermal application. Br J Clin Pharmacol 1990; 30 (2): 292-6
99. Klemsdal TO, Gjesdal K, Zahlsen K. Physical exercise increases plasma concentrations of nicotine during treatment with a nicotine patch. Br J Clin Pharmacol 1995; 39 (6): 677-9
100. Fung HL, Blei A, Chong S. Interpretation of nitrate plasma concentrations: effect of cardiac output on nitroglycerin pharmacokinetics in experimental animals. Eur Heart J 1988; 9 Suppl A: 39-43
101. Blei AT, Friedman S, Gottstein J, et al. Pharmacokinetic-hemodynamic interactions between vasopressin and nitroglycerin: comparison between intravenous and cutaneous routes of nitrate delivery. Hepatology 1985; 5 (2): 264-70
102. Vanakoski J, Seppala T. Heat exposure and drugs: a review of the effects of hyperthermia on pharmacokinetics. Clin Pharmacokinet 1998; 34 (4): 311-22
103. Roth JV. Warm air convection heating blankets may increase the absorption of transdermal nitroglycerin. Anesthesiology 1997; 86 (5): 1208-9
104. Haebisch EM. Transdermal glyceryl trinitrate (nitroglycerin) in healthy persons: acute effects on skin temperature and hemodynamic orthostatic response. Rev Paul Med 1995; 113 (5): 973-82
105. Curry SH, Kwon HR. Influence of posture on plasma nitroglycerin. Br J Clin Pharmacol 1985; 19 (3): 403-4
106. Heidemann R, Beckenbauer C, Woodcock BG. Effect of posture on glyceryl trinitrate plasma concentrations following transdermal application. Br J Clin Pharmacol 1987; 23 (2): 246-7
107. Cahalan MK, Hashimoto Y, Aizawa K, et al. Elderly, conscious patients have an accentuated hypotensive response to nitroglycerin. Anesthesiology 1992; 77 (4): 646-55
108. Alpert JS. Nitrate therapy in the elderly. Am J Cardiol 1990; 65 (21): 23J-7J
109. Müanzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995; 95 (1): 187-94
110. Münzel T, Li H, Mollnau H, et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression. NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res 2000; 86 (1): E7-E12
111. Fink B, Dikalov S, Bassenge E. A new approach for extracellular spin trapping of nitroglycerin-induced superoxide radicals both in vitro and in vivo. Free Radic Biol Med 2000; 28 (1): 121-8
112. Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987; 317 (13): 799-804
113. Dupuis J, Lalonde G, Lemieux R, et al. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990; 16 (4): 923-31
114. Parker JD, Parker JO. Effect of therapy with an angiotensin-converting enzyme inhibitor on hemodynamic and counterregulatory responses during continuous therapy with nitroglycerin. J Am Coll Cardiol 1993; 21 (6): 1445-53
115. Sage PR, de la Lande IS, Stafford I, et al. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation 2000; 102 (23): 2810-5
116. Bauer JA, Fung HL. Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Pharm Res 1994; 11 (6): 816-23
117. Bauer JA, Balthasar JP, Fung HL. Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure. Pharm Res 1997; 14 (9): 1140-5
118. Reiniger G, Lehmann G. Increasing nitroglycerin release from patches enables circumvention of early nitrate tolerance. Cardiovasc Drugs Ther 1998; 12 (2): 217-24
119. Pepine CJ, Lopez LM, Bell DM, et al. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: results of the second transdermal intermittent dosing evaluation study (TIDES-II). J Am Coll Cardiol 1997; 30: 955-61